Redx Announces Appointment of Chief Medical Officer
27 Oct 2020
Redx Pharma announces appointment of leading oncology drug developer, Dr Jane Robertson, as Chief Medical Officer
Alderley Park, 27 October 2020, Redx Pharma plc (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, is pleased to announce that it has appointed Dr Jane Robertson as Chief Medical Officer. Jane is a well respected UK haemato-oncologist with over 17 years’ experience of clinical development in oncology and has a breadth of experience investigating multiple tumours and agents including VEGF inhibitors, anti-hormonals, PARP inhibitors, nucleotide analogs and most recently cell therapies. She will commence her role at Redx on 1 March 2021.
Jane joins Redx from her position as Chief Medical Officer at Achilles Therapeutics Ltd, a biotech company focused on the creation of a personalized T cell therapy directed against clonal tumour neoantigens. During her tenure at Achilles, the Company progressed its lead candidate into two clinical trials. Prior to Achilles, Jane served as the Chief Medical Officer at Nucana Biomed Ltd and at Kesios Therapeutics Ltd. She has previously also held a number of senior R&D leadership roles at AstraZeneca Oncology, notably leading the development of the first in class PARP inhibitor, olaparib. Jane originally trained in general medicine and haematology, working in clinical practice and translational research settings, and sub-specialising in haemato-oncology; she remains General Medical Council registered.
Lisa Anson, Chief Executive Officer of Redx Pharma commented: “We are absolutely delighted that Jane has chosen to join our team at this exciting stage in Redx’s development. As our Chief Medical Officer, her extensive and varied experience in big pharma, biotech and clinical practice, will be invaluable as we further progress our pipeline into clinical development.”
Jane Robertson, incoming Chief Medical Officer, Redx Pharma commented: “I have been very impressed by Redx and its outstanding scientific team, and am really looking forward to the opportunity to progress the Company’s promising pipeline into differentiated clinical stage programmes in the treatment of fibrotic diseases and cancer. With data expected from Redx’s Phase 1 RXC004 study in H1 2021, this feels like a particularly exciting time to be joining the Company.”
Following a handover, Dr Andrew Saunders will leave Redx after 3 years as Chief Medical Officer to pursue other opportunities. Lisa Anson added, “On behalf of all of Redx and the Board, I would like to thank Andrew for his great work in overseeing the transition of RXC004 into phase 1 and his strategic guidance in our planned future development plans for RXC004.”
For further information, please contact:
|Redx Pharma Plc||T: +44 1625 469 918|
|Iain Ross, Chairman
Lisa Anson, Chief Executive
|SPARK Advisory Partners Limited (Nominated Adviser)||T: +44 203 368 3550|
|Matt Davis/Andrew Emmott|
|WG Partners LLP (Joint Broker)||T: +44 20 3705 9330|
|Claes Spång/ Chris Lee/ David Wilson
|FTI Consulting||T: +44 20 3727 1000|
|Simon Conway/Ciara Martin|
About Redx Pharma Plc
Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical proof of concept. Redx’s lead oncology asset, RXC004, is currently in a phase 1 study in patients with advanced malignancies [with top line data expected in H1 2021] and the Company’s selective ROCK2 inhibitor, RXC007, is expected to enter a phase 1 clinical study in H1 2021.
The Company’s core capability of converting medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically validated targets has been recognized by others. Over the last three years the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).